Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021.
| Last: | $3.1701 |
|---|---|
| Change Percent: | 6.56% |
| Open: | $3 |
| Close: | $2.975 |
| High: | $3.19 |
| Low: | $2.92 |
| Volume: | 555,566 |
| Last Trade Date Time: | 03/09/2026 12:44:49 pm |
| Market Cap: | $499,596,451 |
|---|---|
| Float: | 52,800,160 |
| Insiders Ownership: | 10.86% |
| Institutions: | 30 |
| Short Percent: | N/A |
| Industry: | Biotechnology & Life Sciences |
| Sector: | Healthcare |
| Website: | https://neumoratx.com |
| Country: | US |
| City: | Watertown |
Get Instant Newsletter Alerts to your Mobile Device and Email as soon as the News or Alerts hit the wire.
**MWN-AI FAQ is based on asking OpenAI questions about Neumora Therapeutics Inc. (NASDAQ: NMRA).
Link your X account with Market Wire News to automatically tweet trending stocks news and your portfolio stocks news.